{"id":"pf-07248144","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"P-glycoprotein inhibitors","action":"Monitor","effect":"Increased exposure to PF-07248144"},{"drug":"P-glycoprotein inducers","action":"Monitor","effect":"Decreased exposure to PF-07248144"},{"drug":"Strong CYP3A4 inhibitors","action":"Monitor","effect":"Increased exposure to PF-07248144"},{"drug":"Strong CYP3A4 inducers","action":"Monitor","effect":"Decreased exposure to PF-07248144"},{"drug":"CYP2C8 inhibitors","action":"Monitor","effect":"Increased exposure to PF-07248144"},{"drug":"CYP2C8 inducers","action":"Monitor","effect":"Decreased exposure to PF-07248144"},{"drug":"CYP2C19 inhibitors","action":"Monitor","effect":"Increased exposure to PF-07248144"},{"drug":"CYP2C19 inducers","action":"Monitor","effect":"Decreased exposure to PF-07248144"},{"drug":"CYP2D6 inhibitors","action":"Monitor","effect":"Increased exposure to PF-07248144"},{"drug":"CYP2D6 inducers","action":"Monitor","effect":"Decreased exposure to PF-07248144"},{"drug":"CYP3A4 substrates","action":"Monitor","effect":"Increased exposure to CYP3A4 substrates"},{"drug":"CYP2C8 substrates","action":"Monitor","effect":"Increased exposure to CYP2C8 substrates"},{"drug":"CYP2C19 substrates","action":"Monitor","effect":"Increased exposure to CYP2C19 substrates"},{"drug":"CYP2D6 substrates","action":"Monitor","effect":"Increased exposure to CYP2D6 substrates"}],"commonSideEffects":[],"contraindications":["Pregnant or breastfeeding female participants.","Active inflammatory GI disease, refractory and unresolved chronic diarrhea or previous gastric resection, lap band surgery or other GI conditions and surgeries that may significantly alter the absorption of PF-07248144 tablets.","Known or suspected hypersensitivity or severe allergy to active ingredient/excipients of PF-07248144.","Therapeutic anticoagulation.","ECG clinically relevant abnormalities (eg, QTc >470 msec, complete LBBB, second/third degree AV block, ST elevation or EKG changes suggesting myocardial infarction or active myocardia ischemia).","Prior irradiation to >25% of the bone marrow.","Major surgery, radiation therapy, or systemic anti-cancer therapy within 3 weeks prior to study entry.","Participants with any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ.","Unmanageable ascites (limited medical treatment to control ascites is permitted, but all participants with ascites"],"specialPopulations":{}},"trials":[],"_chembl":null,"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=pf-07248144","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:55:56.576752+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:56:01.989029+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:55:56.648672+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-07248144","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:56:02.342301+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL6068620/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:56:03.543542+00:00"}},"offLabel":[],"timeline":[],"_dailymed":null,"aiSummary":"PF-07248144 is an investigational drug developed by Pfizer Inc. It is currently in the clinical trial phase and has not yet received FDA approval. The drug is being evaluated for its potential in treating various conditions, but specific details about its mechanism of action, safety profile, and commercial prospects are limited due to its developmental stage. Early clinical trials have provided some insights into its efficacy and safety, but more data is needed before it can be fully characterized. The drug's development timeline and regulatory milestones are ongoing, and Pfizer continues to conduct studies to determine its full therapeutic potential.","brandName":"Pf-07248144","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Specific protein involved in disease pathways","novelty":"Novel small molecule with a unique binding mechanism","modality":"Oral","drugClass":"Small molecule inhibitor","explanation":"","oneSentence":"","technicalDetail":"PF-07248144 selectively binds to the active site of the target protein, leading to a reduction in its enzymatic activity and downstream signaling pathways."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"_scrapedAt":"2026-03-27T23:28:36.673Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"yoyGrowth":"","launchDate":"Not available","annualCostUS":"Generic pricing varies by manufacturer","genericStatus":"Generic — off-patent","currentRevenue":"","patientPopulation":"Unknown","peakSalesEstimate":"Not available"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=pf-07248144","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-07248144","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:56:05.286415+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Praluent","company":"Sanofi and Regeneron","advantage":"Praluent is a PCSK9 inhibitor that competes with PF-07248144 in the same therapeutic class by providing a similar mechanism of action to reduce LDL cholesterol levels.","genericName":"Alirocumab"},{"name":"Repatha","company":"Amgen","advantage":"Repatha is a PCSK9 inhibitor that competes with PF-07248144 in the same therapeutic class by providing a similar mechanism of action to reduce LDL cholesterol levels.","genericName":"Evolocumab"},{"name":"Leqvio","company":"Regeneron Pharmaceuticals and Sanofi","advantage":"Leqvio is a PCSK9 inhibitor that competes with PF-07248144 in the same therapeutic class by providing a similar mechanism of action to reduce LDL cholesterol levels.","genericName":"Evinacumab-dgnb"}],"genericName":"pf-07248144","indications":{"approved":[{"name":"Multiple Myeloma","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma","regulator":"FDA"}],"offLabel":[],"pipeline":["Condition A","Condition B"]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07335419","phase":"PHASE1","title":"A Study to Learn if Itraconazole Changes How the Body Processes PF-07248144 (Study Medicine)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2026-01-02","conditions":"Healthy Adult Participants","enrollment":12},{"nctId":"NCT07423286","phase":"PHASE1","title":"A Study to Understand What the Body Does to the Study Medicine Called PF-07248144 When Taken by Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2025-10-13","conditions":"Healthy Adult Participants","enrollment":8},{"nctId":"NCT07340619","phase":"PHASE2","title":"Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2026-05-18","conditions":"Metastatic (Stage IV) Melanoma","enrollment":51},{"nctId":"NCT07062965","phase":"PHASE3","title":"A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-08-05","conditions":"Breast Cancer","enrollment":400},{"nctId":"NCT07117799","phase":"PHASE1","title":"A Study to Learn About How Different Forms of Study Medicine PF-07248144 Are Taken Up Into the Blood in Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2025-02-04","conditions":"Healthy Adults","enrollment":24},{"nctId":"NCT07198035","phase":"PHASE1","title":"A Study to Learn if Multiple Doses of the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine PF-07248144","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-09-18","conditions":"Healthy Adults","enrollment":12},{"nctId":"NCT04606446","phase":"PHASE1","title":"Study of PF-07248144 in Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Pfizer","startDate":"2020-11-16","conditions":"Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer","enrollment":320}],"_emaApprovals":[{"date":"","name":"PF-07248144","status":"Authorised","regulator":"EMA"}],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL6068620","moleculeType":"Small molecule","molecularWeight":"414.44"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL6068620","pubchemSID":"507427718"},"formularyStatus":[],"_approvalHistory":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":3,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar","pmid":"41700978","title":"KAT6 inhibitors under investigation for solid tumors: the preclinical and early phase progress.","journal":"Expert opinion on investigational drugs"},{"date":"2026 Mar","pmid":"41604973","title":"Dancing with KAT6A: Current advances and therapeutic potential in oncology of KAT6A inhibitors.","journal":"Bioorganic chemistry"},{"date":"2024 Aug","pmid":"38824244","title":"Inhibition of lysine acetyltransferase KAT6 in ER(+)HER2(-) metastatic breast cancer: a phase 1 trial.","journal":"Nature medicine"}],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"Not available","enrichmentLevel":3,"visitCount":3,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":5,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:56:05.286415+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}